Platelet miRNAs and cardiovascular diseases

Fuentes, Eduardo; Palomo, Iván; Alarcón, Marcelo

doi:10.1016/j.lfs.2015.04.016

Cited by 27 publications

(32 citation statements)

References 266 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous miRNAs have a functional role in multiple steps of platelet biogenesis, including hematopoietic lineage commitment, differentiation, proliferation, maturation, and release into the circulation [11]. Although platelets lack a nucleus, they express abundant pre- and mature miRNAs [9, 37]. Platelets also contain Dicer and Argonaute 2, two protein complexes that are part of the miRNA regulation machinery [6, 38].…”

Section: Discussionmentioning

confidence: 99%

“…Increasing amounts of data have demonstrated important mechanistic roles for platelet miRNAs in hemostasis, thrombosis, coronary artery disease, and stroke [10, 41]. Therefore, platelet miRNAs are implicated in the pathogenesis of atherothrombotic and cardiovascular diseases [37]. Recently, the possibility of using miRNAs as therapeutic tools in the treatment of cardiovascular diseases has emerged, based on the potential of miRNAs to manipulate the pathologic mechanisms underlying such diseases [39, 42].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality

Kim

Choi

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

The microRNA (miRNA) is a small non-coding RNA molecule that modulates gene expression at the posttranscriptional level. Platelets have a crucial role in both hemostasis and thrombosis, a condition that can occlude a cerebral artery and cause ischemic stroke. miR-130b, miR-200b, and miR-495 are potential genetic modulators involving platelet production and activation. We hypothesized that single nucleotide polymorphisms (SNPs) in these miRNAs might potentially contribute to the susceptibility to ischemic stroke and post-stroke mortality. This study included 523 ischemic stroke patients and 400 control subjects. We investigated the association of three miRNA SNPs (miR-130bT>C, miR-200bT>C, and miR-495A>C) with ischemic stroke prevalence and post-stroke mortality. In the multivariate logistic regression, there was no statistically significant difference in the distribution of miR-130bT>C, miR-200bT>C, or miR-495A>C between the ischemic stroke and control groups. In the subgroup analysis based on ischemic stroke subtype, the miR-200b CC genotype was less frequently found in the large-artery atherosclerosis stroke subtype compared with controls (TT+CT vs CC; adjusted odds ratio for CC, 0.506; 95% confidence interval, 0.265–0.965). During a mean follow-up period of 4.80 ± 2.11 years after stroke onset, there were 106 all-cause deaths among the 523 stroke patients. Multivariate Cox regression analysis did not find a significant association between post-stroke mortality and three miRNA SNPs. Our findings suggest that the functional SNP of miR-200b might be responsible for the susceptibility to large-artery atherosclerotic stroke.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality

Kim

Choi

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…miR-223 controls erythrocyte membrane protein band 4.1 like 3 ( EPB41L3 ) gene, known to be associated with atherosclerosis. However, miR-126 regulates a VCAM-1 gene, known to be linked with endothelial dysfunction and atherosclerosis, indicating important role of platelet-derived miRNAs in regulation of key genes associated with atherosclerotic vascular complications [228, 229]. In another study, N -acetylcysteine was reported to provide protection against the risk of stroke by altering both systemic as well as vascular prothrombotic responses and correcting levels of antioxidants in T2DM patients [230].…”

Section: Platelets Hyperactivity In T2dmmentioning

confidence: 99%

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Kaur

Singh

2018

Cardiovasc Diabetol

494

363

View full text Add to dashboard Cite

The incidence and prevalence of diabetes mellitus is rapidly increasing worldwide at an alarming rate. Type 2 diabetes mellitus (T2DM) is the most prevalent form of diabetes, accounting for approximately 90–95% of the total diabetes cases worldwide. Besides affecting the ability of body to use glucose, it is associated with micro-vascular and macro-vascular complications. Augmented atherosclerosis is documented to be the key factor leading to vascular complications in T2DM patients. The metabolic milieu of T2DM, including insulin resistance, hyperglycemia and release of excess free fatty acids, along with other metabolic abnormalities affects vascular wall by a series of events including endothelial dysfunction, platelet hyperactivity, oxidative stress and low-grade inflammation. Activation of these events further enhances vasoconstriction and promotes thrombus formation, ultimately resulting in the development of atherosclerosis. All these evidences are supported by the clinical trials reporting the importance of endothelial dysfunction and platelet hyperactivity in the pathogenesis of atherosclerotic vascular complications. In this review, an attempt has been made to comprehensively compile updated information available in context of endothelial and platelet dysfunction in T2DM.

show abstract

“…A recent works postulates the possibility of using miRNAs as biomarkers of atherosclerosis and ischemic episodes [4, 63] (Table 1). The miRNAs present in platelets may exert important regulatory functions in synthesis of proteins, which are involved in platelet activation pathways associated with platelet hyperactivity leading to thrombus formation.…”

Section: Discussionmentioning

confidence: 99%

Platelets miRNA as a Prediction Marker of Thrombotic Episodes

et al. 2016

View full text Add to dashboard Cite

The blood platelets are crucial for the coagulation physiology to maintain haemostatic balance and are involved in various pathologies such as atherosclerosis and thrombosis. The studies of recent years have shown that anucleated platelets are able to succeed protein synthesis. Additionally, mRNA translation in blood platelets is regulated by miRNA molecules. Recent works postulate the possibility of using miRNAs as biomarkers of atherosclerosis and ischemic episodes. This review article describes clinical studies that presented blood platelets miRNAs expression profile changes in different thrombotic states, which suggest use of these molecules as predictive biomarkers.

show abstract

Platelet miRNAs and cardiovascular diseases

Cited by 27 publications

References 266 publications

Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality

Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Platelets miRNA as a Prediction Marker of Thrombotic Episodes

Contact Info

Product

Resources

About